Michael R. Baria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael R. Baria has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Robert Magnussen
Associate Professor, Department of Physical Medicine and Rehabilitation. Sports Medicine Research Institute. The Ohio State University, Columbus, Ohio, USA
6 shared publicationsChristopher Kaeding
Associate Professor, Department of Physical Medicine and Rehabilitation. Sports Medicine Research Institute. The Ohio State University, Columbus, Ohio, USA
5 shared publicationsDavid Flanigan
Associate Professor, Department of Physical Medicine and Rehabilitation. Sports Medicine Research Institute. The Ohio State University, Columbus, Ohio, USA
5 shared publicationsJames Borchers
Department of Family and Community Medicine, The Ohio State University, Columbus, Ohio, USA
4 shared publicationsSushmitha Durgam
Department of Clinical Sciences, College of Veterinary Medicine, Columbus, USA
4 shared publicationsTyler Barker
Ohio State Sports Medicine Research Institute, Columbus, USA
4 shared publications
Latest Publications
- 5 November 2026
- Published by SAGE Publications in The American Journal of Sports Medicine
A Single Intra-articular Injection of Autologous Stromal Vascular Fraction for Moderate-to-Severe Knee Osteoarthritis: Results of a Multicenter Randomized Placebo-Controlled Trial With 12-Month Follow-up
Background: This randomized controlled trial evaluated the 12-month outcomes of a single intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF), prepared and administered during the same clinical encounter, for the treatment of moderate-to-severe knee osteoarthritis (OA). Purpose/Hypothesis: To evaluate the efficacy of a single intra-articular injection of 25 million autologous adipose-derived SVF cells for moderate-to-severe knee OA, compared with placebo, at 12 months. The authors hypothesized that SVF-treated patients would demonstrate a significantly greater responder rate based on prespecified clinically meaningful improvements in pain and function derived from composite outcomes of the index and contralateral knees. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: Adults aged 35 to 85 years with symptomatic unilateral or bilateral knee OA were eligible if the index knee demonstrated a Western Ontario and McMaster Universities Osteoarthritis Index pain score of ≥8, an Outerbridge grade of 2 to 4 on magnetic resonance imaging (MRI), and a Kellgren-Lawrence grade of 2 to 4 on radiographs. Autologous adipose-derived SVF was prepared using a point-of-care isolation system during the same clinical encounter, assessed against predefined release criteria, and administered as a single intra-articular injection into the index knee. MRI of the index knee was obtained at baseline and at 12 months. Results: A total of 618 participants were assessed for eligibility, of whom 114 were randomized (SVF, n = 83; placebo, n = 31). At 12 months, a single intra-articular injection of 25 million SVF cells demonstrated statistical superiority over placebo for the primary composite clinical endpoint. The responder rate was 51.8% (43/83) in the SVF group compared with 29% (9/31) in the placebo group (difference, 22.8% [95% CI, 3.5%-42%]; 1-sided P = .0149). No serious investigational device-related adverse events were reported. Conclusion: A single intra-articular injection of 25 million autologous adipose-derived SVF cells resulted in statistically superior and clinically meaningful improvements in pain and function at 12 months compared with placebo, with no serious investigational device-related adverse events reported. Registration: IDE 16734; ClinicalTrials.gov NCT04440189.
- 5 November 2026
- Published by SAGE Publications in The American Journal of Sports Medicine
A Single Intra-articular Injection of Autologous Stromal Vascular Fraction for Moderate-to-Severe Knee Osteoarthritis: Results of a Multicenter Randomized Placebo-Controlled Trial With 12-Month Follow-up
Background: This randomized controlled trial evaluated the 12-month outcomes of a single intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF), prepared and administered during the same clinical encounter, for the treatment of moderate-to-severe knee osteoarthritis (OA). Purpose/Hypothesis: To evaluate the efficacy of a single intra-articular injection of 25 million autologous adipose-derived SVF cells for moderate-to-severe knee OA, compared with placebo, at 12 months. The authors hypothesized that SVF-treated patients would demonstrate a significantly greater responder rate based on prespecified clinically meaningful improvements in pain and function derived from composite outcomes of the index and contralateral knees. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: Adults aged 35 to 85 years with symptomatic unilateral or bilateral knee OA were eligible if the index knee demonstrated a Western Ontario and McMaster Universities Osteoarthritis Index pain score of ≥8, an Outerbridge grade of 2 to 4 on magnetic resonance imaging (MRI), and a Kellgren-Lawrence grade of 2 to 4 on radiographs. Autologous adipose-derived SVF was prepared using a point-of-care isolation system during the same clinical encounter, assessed against predefined release criteria, and administered as a single intra-articular injection into the index knee. MRI of the index knee was obtained at baseline and at 12 months. Results: A total of 618 participants were assessed for eligibility, of whom 114 were randomized (SVF, n = 83; placebo, n = 31). At 12 months, a single intra-articular injection of 25 million SVF cells demonstrated statistical superiority over placebo for the primary composite clinical endpoint. The responder rate was 51.8% (43/83) in the SVF group compared with 29% (9/31) in the placebo group (difference, 22.8% [95% CI, 3.5%-42%]; 1-sided P = .0149). No serious investigational device-related adverse events were reported. Conclusion: A single intra-articular injection of 25 million autologous adipose-derived SVF cells resulted in statistically superior and clinically meaningful improvements in pain and function at 12 months compared with placebo, with no serious investigational device-related adverse events reported. Registration: IDE 16734; ClinicalTrials.gov NCT04440189.
- 7 October 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Osteitis Condensans Ilii Presenting as Right-Sided Low Back Pain
Was not provided for this article.
- 7 October 2026
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Osteitis Condensans Ilii Presenting as Right-Sided Low Back Pain
Was not provided for this article.
- 1 April 2025
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 104 (12) , e166-e167
Atraumatic Tensor Fascia Latae Teary Complicating a Gluteal Cuff Injury
An abstract is unavailable. This article is available as a PDF only.
- 1 April 2025
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 104 (12) , e166-e167
Atraumatic Tensor Fascia Latae Teary Complicating a Gluteal Cuff Injury
An abstract is unavailable. This article is available as a PDF only.
- 27 March 2025
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 104 (11) , 1036-1037
Posterior Glenoid Rim Fracture as an Indication of Posterior Shoulder Instability
An abstract is unavailable. This article is available as a PDF only.
- 27 March 2025
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 104 (11) , 1036-1037
Posterior Glenoid Rim Fracture as an Indication of Posterior Shoulder Instability
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 15 January 2025
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 26 (1) , 1-10
Effects of adipose allograft matrix on viability of humeral head cartilage and rotator cuff tendon
Rotator cuff repairs may fail because of compromised blood supply, suture anchor pullout, or poor fixation to bone. To augment the repairs and promote healing of the tears, orthobiologics, such a platelet-rich plasma (PRP), and biologic scaffolds have been applied with mixed results. Adipose allograft matrix (AAM), which recruits native cells to damaged tissues, may also be a potential treatment for rotator cuff tears. To assess the potential use of AAM on rotator cuff tears, humeral head cartilage and subscapularis tendon were collected from patients undergoing reverse shoulder arthroplasty (RSA). Punch biopsies of the tissues were used to create explants for tissue culture, and the remaining tissue was digested to isolate the chondrocytes and tenocytes for cell culture. Explants and cells were then cultured in media containing AAM. After 48 h, the tissues and cells were measured for cell viability, cell proliferation, extracellular matrix (ECM) and metalloproteinase (MMP) gene expression and for MMP, inflammatory cytokine, and growth factor concentrations. Cell viability was increased in humeral head chondrocytes and rotator cuff tenocytes cultured with AAM. Gene expression of the matrix proteoglycan, aggrecan, and of the proteolytic enzyme MMP-13 were downregulated in humeral head chondrocytes. MMP-13 concentrations were increased in subscapularis tenocytes and in humeral head chondrocyte/subscapularis tenocyte co-cultures. The anti-inflammatory cytokine, IL-1ra was increased in cartilage/tendon explant co-cultures. TGF-β1 concentrations were increased in chondrocytes, but decreased in tenocytes. Overall, AAM had no significant negative effects on the cells or explants. The results of these experiments provide the basis for the future use of AAM as a scaffolding for tissue engineering, preclinical animal models of rotator cuff tear and glenohumeral osteoarthritis, and clinical models. Not applicable.
- 15 January 2025
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 26 (1) , 1-10
Open AccessEffects of adipose allograft matrix on viability of humeral head cartilage and rotator cuff tendon
Rotator cuff repairs may fail because of compromised blood supply, suture anchor pullout, or poor fixation to bone. To augment the repairs and promote healing of the tears, orthobiologics, such a platelet-rich plasma (PRP), and biologic scaffolds have been applied with mixed results. Adipose allograft matrix (AAM), which recruits native cells to damaged tissues, may also be a potential treatment for rotator cuff tears. To assess the potential use of AAM on rotator cuff tears, humeral head cartilage and subscapularis tendon were collected from patients undergoing reverse shoulder arthroplasty (RSA). Punch biopsies of the tissues were used to create explants for tissue culture, and the remaining tissue was digested to isolate the chondrocytes and tenocytes for cell culture. Explants and cells were then cultured in media containing AAM. After 48 h, the tissues and cells were measured for cell viability, cell proliferation, extracellular matrix (ECM) and metalloproteinase (MMP) gene expression and for MMP, inflammatory cytokine, and growth factor concentrations. Cell viability was increased in humeral head chondrocytes and rotator cuff tenocytes cultured with AAM. Gene expression of the matrix proteoglycan, aggrecan, and of the proteolytic enzyme MMP-13 were downregulated in humeral head chondrocytes. MMP-13 concentrations were increased in subscapularis tenocytes and in humeral head chondrocyte/subscapularis tenocyte co-cultures. The anti-inflammatory cytokine, IL-1ra was increased in cartilage/tendon explant co-cultures. TGF-β1 concentrations were increased in chondrocytes, but decreased in tenocytes. Overall, AAM had no significant negative effects on the cells or explants. The results of these experiments provide the basis for the future use of AAM as a scaffolding for tissue engineering, preclinical animal models of rotator cuff tear and glenohumeral osteoarthritis, and clinical models. Not applicable.
- 12 December 2024
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Response to letter to the editor: “The relationship of body mass index on patient reported outcomes after platelet-rich plasma versus microfragmented adipose tissue for knee osteoarthritis: A secondary analysis of a randomized controlled trial”
An abstract is unavailable. This article is available as a PDF only.
- 12 December 2024
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
Response to letter to the editor: “The relationship of body mass index on patient reported outcomes after platelet-rich plasma versus microfragmented adipose tissue for knee osteoarthritis: A secondary analysis of a randomized controlled trial”
An abstract is unavailable. This article is available as a PDF only.
- 29 March 2024
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 103 (11) , 1006-1011
Relationship of Body Mass Index on Patient-Reported Outcomes After Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis
Objective: Body mass index is known to contribute to outcomes for patients with knee osteoarthritis. Furthermore, body mass index influences the protein expression of orthobiologic treatments like platelet-rich plasma and microfragmented adipose tissue. We performed a secondary analysis of the association of body mass index with patient-reported outcomes for patients with knee osteoarthritis who received either platelet-rich plasma or microfragmented adipose tissue injections. Methods: Seventy-one patients with knee osteoarthritis were randomized to receive a single ultrasound-guided injection of platelet-rich plasma or microfragmented adipose tissue. Platelet-rich plasma was created from 180 cc of anticoagulated blood and processed using a double-spin, buffy-coat concentration system. Microfragmented adipose tissue was created using autologous lipoaspirate that was processed according to minimal manipulation guidelines. Patient-reported outcomes and osteoarthritis outcome scores (Knee Osteoarthritis and injury Outcome Score) were tracked for 12 mos. Results: Forty-nine patients (platelet-rich plasma = 23, microfragmented adipose tissue = 26) completed 12-mo follow-up. Knee Osteoarthritis and injury Outcome Score quality of life and activity of daily living subscores were inversely correlated (both P < 0.05) with body mass index in the microfragmented adipose tissue but not platelet-rich plasmagroup. Knee Osteoarthritis and injury Outcome Score pain and sport subscores showed a trend toward inverse correlation with body mass index in the microfragmented adipose tissue group (P = 0.07 and P = 0.06, respectively), but not platelet-rich plasma. Conclusions: Body mass index was negatively associated with patient-reported outcomes in patients who received microfragmented adipose tissue injections for knee osteoarthritis, but not for patients receiving platelet-rich plasma.
- 29 March 2024
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 103 (11) , 1006-1011
Relationship of Body Mass Index on Patient-Reported Outcomes After Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis
Objective: Body mass index is known to contribute to outcomes for patients with knee osteoarthritis. Furthermore, body mass index influences the protein expression of orthobiologic treatments like platelet-rich plasma and microfragmented adipose tissue. We performed a secondary analysis of the association of body mass index with patient-reported outcomes for patients with knee osteoarthritis who received either platelet-rich plasma or microfragmented adipose tissue injections. Methods: Seventy-one patients with knee osteoarthritis were randomized to receive a single ultrasound-guided injection of platelet-rich plasma or microfragmented adipose tissue. Platelet-rich plasma was created from 180 cc of anticoagulated blood and processed using a double-spin, buffy-coat concentration system. Microfragmented adipose tissue was created using autologous lipoaspirate that was processed according to minimal manipulation guidelines. Patient-reported outcomes and osteoarthritis outcome scores (Knee Osteoarthritis and injury Outcome Score) were tracked for 12 mos. Results: Forty-nine patients (platelet-rich plasma = 23, microfragmented adipose tissue = 26) completed 12-mo follow-up. Knee Osteoarthritis and injury Outcome Score quality of life and activity of daily living subscores were inversely correlated (both P < 0.05) with body mass index in the microfragmented adipose tissue but not platelet-rich plasmagroup. Knee Osteoarthritis and injury Outcome Score pain and sport subscores showed a trend toward inverse correlation with body mass index in the microfragmented adipose tissue group (P = 0.07 and P = 0.06, respectively), but not platelet-rich plasma. Conclusions: Body mass index was negatively associated with patient-reported outcomes in patients who received microfragmented adipose tissue injections for knee osteoarthritis, but not for patients receiving platelet-rich plasma.
- Open Access
- 18 March 2024
- Published by SAGE Publications in Orthopaedic Journal of Sports Medicine
- Vol. 12 (3)
Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial
Background: Platelet-rich plasma (PRP) is an effective treatment for knee osteoarthritis (OA). Microfragmented adipose tissue (MFAT) is another orthobiologic that holds promise, but data supporting its use are limited. Previous studies showed that MFAT created using the Lipogems device was equivalent to PRP created via noncommercial laboratory-based processes. Purpose: To perform a comparison of commercially available MFAT and PRP systems for treatment of knee OA. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: A total of 71 patients with symptomatic knee OA (Kellgren-Lawrence grades 1-4) were randomized to receive a single injection of either leukocyte-rich PRP (Angel; Arthrex) or MFAT (Lipogems) under ultrasound guidance. Patient-reported outcomes (Knee injury and Osteoarthritis Outcome Score [KOOS], visual analog scale for pain with activities of daily living [VAS pain], and Tegner activity level) were recorded at baseline and at 1, 3, 6, and 12 months after injection. The primary outcome was the KOOS-Pain subscale score at 12 months after injection. Results: Overall, 49 patients completed their 12-month follow-up (PRP group, n = 23; MFAT group, n = 26). All demographic features were similar between groups, except that more men were randomized to the PRP group and more women to the MFAT group. At 12 months posttreatment, KOOS-Pain scores improved in both groups, with no significant group difference (PRP, 78 ± 17.9 vs MFAT, 77.8 ± 19.3; P = .69). Similarly, other KOOS subscales, VAS pain scores, and Tegner scores improved at 12 months, with no differences between treatment groups. Conclusion: Both PRP and MFAT injections for knee OA resulted in improved patient-reported outcomes at 12 months posttreatment, with no differences found between treatments. Registration: NCT04351087 (ClinicalTrials.gov identifier).
- 18 March 2024
- Published by SAGE Publications in Orthopaedic Journal of Sports Medicine
- Vol. 12 (3)
Open AccessMicrofragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial
Background: Platelet-rich plasma (PRP) is an effective treatment for knee osteoarthritis (OA). Microfragmented adipose tissue (MFAT) is another orthobiologic that holds promise, but data supporting its use are limited. Previous studies showed that MFAT created using the Lipogems device was equivalent to PRP created via noncommercial laboratory-based processes. Purpose: To perform a comparison of commercially available MFAT and PRP systems for treatment of knee OA. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: A total of 71 patients with symptomatic knee OA (Kellgren-Lawrence grades 1-4) were randomized to receive a single injection of either leukocyte-rich PRP (Angel; Arthrex) or MFAT (Lipogems) under ultrasound guidance. Patient-reported outcomes (Knee injury and Osteoarthritis Outcome Score [KOOS], visual analog scale for pain with activities of daily living [VAS pain], and Tegner activity level) were recorded at baseline and at 1, 3, 6, and 12 months after injection. The primary outcome was the KOOS-Pain subscale score at 12 months after injection. Results: Overall, 49 patients completed their 12-month follow-up (PRP group, n = 23; MFAT group, n = 26). All demographic features were similar between groups, except that more men were randomized to the PRP group and more women to the MFAT group. At 12 months posttreatment, KOOS-Pain scores improved in both groups, with no significant group difference (PRP, 78 ± 17.9 vs MFAT, 77.8 ± 19.3; P = .69). Similarly, other KOOS subscales, VAS pain scores, and Tegner scores improved at 12 months, with no differences between treatment groups. Conclusion: Both PRP and MFAT injections for knee OA resulted in improved patient-reported outcomes at 12 months posttreatment, with no differences found between treatments. Registration: NCT04351087 (ClinicalTrials.gov identifier).
- 18 May 2023
- Published by Springer Nature
- p. 151-165
Orthobiologic Treatment Options for Injuries in Endurance Athletes
- 18 May 2023
- Published by Springer Nature
- p. 151-165
Orthobiologic Treatment Options for Injuries in Endurance Athletes